Acute Myeloid Leukemia with Core-Binding Factor Rearrangements: A 10-Year Cancer Center Experience.
1/5 보강
[INTRODUCTION] Core-binding factor-acute myeloid leukemia (CBF-AML) is characterized by t(8;21) or inv(16)/t(16;16) chromosomal rearrangements.
APA
Fareed S, Soliman DS, et al. (2026). Acute Myeloid Leukemia with Core-Binding Factor Rearrangements: A 10-Year Cancer Center Experience.. Oncology, 104(1), 10-19. https://doi.org/10.1159/000544049
MLA
Fareed S, et al.. "Acute Myeloid Leukemia with Core-Binding Factor Rearrangements: A 10-Year Cancer Center Experience.." Oncology, vol. 104, no. 1, 2026, pp. 10-19.
PMID
39961289 ↗
Abstract 한글 요약
[INTRODUCTION] Core-binding factor-acute myeloid leukemia (CBF-AML) is characterized by t(8;21) or inv(16)/t(16;16) chromosomal rearrangements.
[METHODS] In this retrospective study of 71 CBF-AML cases from Qatar's National Center for Cancer Care and Research (2013-2022), we analyzed clinicopathological characteristics and survival outcomes.
[RESULTS] The cohort was predominantly male (76%) with a median age of 40 years, and 96% were de novo AML. The t(8;21) translocation was more frequent (69%) than inv(16)/t(16;16). Patients under 40 years showed higher white blood cell counts and blast percentages. Standard "3 + 7" induction chemotherapy (used in 69% of cases) achieved remission in 67% of patients. Median overall survival was 81% at 37 months, with median progression-free survival of 34 months. No significant survival differences were observed based on FLT3-ITD status, translocation type, complex karyotype, KIT mutation status, or allogeneic stem cell transplantation (performed in 19% of patients), though patients under 60 years demonstrated better survival outcomes.
[CONCLUSIONS] This study highlights CBF-AML heterogeneity and challenges established prognostic markers, suggesting a need for risk stratification reassessment, treatment strategy optimization, ELN guideline implementation, and continuous molecular monitoring.
[METHODS] In this retrospective study of 71 CBF-AML cases from Qatar's National Center for Cancer Care and Research (2013-2022), we analyzed clinicopathological characteristics and survival outcomes.
[RESULTS] The cohort was predominantly male (76%) with a median age of 40 years, and 96% were de novo AML. The t(8;21) translocation was more frequent (69%) than inv(16)/t(16;16). Patients under 40 years showed higher white blood cell counts and blast percentages. Standard "3 + 7" induction chemotherapy (used in 69% of cases) achieved remission in 67% of patients. Median overall survival was 81% at 37 months, with median progression-free survival of 34 months. No significant survival differences were observed based on FLT3-ITD status, translocation type, complex karyotype, KIT mutation status, or allogeneic stem cell transplantation (performed in 19% of patients), though patients under 60 years demonstrated better survival outcomes.
[CONCLUSIONS] This study highlights CBF-AML heterogeneity and challenges established prognostic markers, suggesting a need for risk stratification reassessment, treatment strategy optimization, ELN guideline implementation, and continuous molecular monitoring.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
- Humans
- Male
- Female
- Leukemia
- Myeloid
- Acute
- Adult
- Middle Aged
- Retrospective Studies
- Core Binding Factors
- Translocation
- Genetic
- Aged
- Young Adult
- Adolescent
- Gene Rearrangement
- Qatar
- Chromosomal translocations
- Core-binding factor-acute myeloid leukemia
- Prognostic factors
- Risk stratification
- Survival outcomes
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.